Septerna (SEPN) Interest Expenses (2023 - 2026)
Septerna (SEPN) posted quarterly Interest Expenses of $67.8 million for Q1 2026, up 1231.42% year-over-year from $5.1 million in Q1 2025, and down 22.25% quarter-over-quarter from $87.2 million in Q4 2025.
Septerna (SEPN) Interest Expenses (2023 - 2026) Analysis & Trends
Septerna's Interest Expenses history runs 4 years deep, the most recent figure standing at $67.8 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 1231.42% year-over-year to $67.8 million; the TTM figure through Mar 2026 stood at $67.8 million (up 1231.42% YoY), while the FY2025 annual figure was $87.2 million, up 62.35% from the prior year.
- Interest Expenses for Q1 2026 stood at $67.8 million, down from $87.2 million in the prior quarter.
- The five-year high for Interest Expenses was $87.2 million in Q4 2025, with the low at $2.3 million in Q4 2023.
- The 4-year median for Interest Expenses is $43.7 million (2024), against an average of $40.0 million.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses surged 2248.32% in 2024, then climbed 29.1% in 2025.
- Septerna's Interest Expenses stood at $2.3 million in 2023, then soared by 2248.32% to $53.7 million in 2024, then surged by 62.35% to $87.2 million in 2025, then retreated by 22.25% to $67.8 million in 2026.
- Business Quant data shows SEPN's Interest Expenses at $67.8 million in Q1 2026, $87.2 million in Q4 2025, and $49.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Septerna | 2.08 Bn | 2.08 Bn | - | 113.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 113.78 Mn |
| Jun 30, 2026 | 113.78 Mn |
| Mar 31, 2026 | 67.80 Mn |
| Mar 31, 2026 | 67.80 Mn |
| Dec 31, 2025 | 87.19 Mn |
| Dec 31, 2025 | 87.19 Mn |
| Sep 30, 2025 | 49.20 Mn |
| Sep 30, 2025 | 49.20 Mn |
| Jun 30, 2025 | 16.77 Mn |
| Jun 30, 2025 | 16.77 Mn |
| Mar 31, 2025 | 5.09 Mn |
| Mar 31, 2025 | 5.09 Mn |
| Dec 31, 2024 | 53.71 Mn |
| Dec 31, 2024 | 53.71 Mn |
| Sep 30, 2024 | 38.11 Mn |
| Sep 30, 2024 | 38.11 Mn |
| Dec 31, 2023 | 2.29 Mn |
| Dec 31, 2023 | 2.29 Mn |